A new study from TSRI researchers reveals the role of a gene called Mkx in maintaining and strengthening tendons in animal models. The findings may bring doctors closer to using gene therapies to grow and repair tendons.
Researchers from Scripps Florida have discovered a link between bipolar disorder and the striatum, a brain region involved in motor planning and reward perception. The study identified 14 genes differentially expressed in bipolar patients compared to non-bipolar controls, suggesting a causal role in the disorder.
The Scripps Research Institute has received a $20 million award to support a national precision medicine initiative, enrolling 350,000 participant-volunteers. The program aims to engage one million or more U.S. participants to improve disease prevention and treatment based on individual differences in lifestyle, environment, and genetics.
Researchers at TSRI have advanced efforts to design an AIDS vaccine by stabilizing the HIV Envelope glycoprotein trimer and designing novel nanoparticles that mimic the virus. The stabilization strategy improves the protein's properties, allowing for the creation of HIV-like particles that can prompt the body to fight the real virus.
Researchers have identified a protein called GlyRS that contributes to higher mortality in breast cancer patients by launching cancer growth. The study suggests targeting this protein could lead to the development of new anti-cancer therapies.
Chemist Phil Baran of TSRI has won a Blavatnik National Award for his transformative research in natural product synthesis and development of new synthetic methodology. This award recognizes the potential of his work to create life-saving medicines, including the approved treatment of skin cancer.
Researchers have identified 16 distinct neuronal subtypes in the human cerebral cortex, revealing a surprising diversity in gene expression. This discovery provides insights into brain function and may shed light on diseases such as Alzheimer's and Parkinson's.
Scientists at Scripps Research Institute developed a powerful new method to find drug candidates that bind to specific proteins. The technique can be applied to thousands of distinct proteins and has successfully identified selective inhibitors for two caspase enzymes, which play key roles in multiple diseases.
Researchers from Scripps Research Institute have been awarded $1.3 million to optimize probes for a new cancer treatment approach. The study focuses on the retinoic acid receptor-related orphan receptors (ROR) gamma and molecules that bind to it, aiming to trigger immune cells to attack tumor cells.
The TSRI graduate program has received a new $2 million gift from the Skaggs family to support exceptional students in advanced training at the intersection of biology and chemistry. The gift will enhance research programs and provide financial support, including a first-year stipend and up to $5,000 in subsequent years.
Researchers uncover Scribble protein's role in orchestrating intracellular signaling processes for forgetting, which could lead to selective memory removal or inhibition of Alzheimer's disease progression. The study uses Drosophila fruit flies as a model, showing that reducing Scribble expression enhances memory retention.
Researchers have created a drug candidate that targets and neutralizes the RNA structure causing an incurable progressive disease, spinocerebellar ataxia type 10. The compound, 2AU-2, improves several aspects of cells taken from patients with SCA10, offering new hope for treating dozens of incurable diseases.
Scientists at TSRI have discovered a mechanism that turns mutant cells into aggressive cancers. The research identifies the role of POT1 mutations and their impact on the cell's ability to repair DNA damage.
Researchers found that stimulation from outside world guides neurons' early development, leading to two different types of inhibitory neurons. This adds complexity and regulation to brain circuitry, with implications for treating neurological disorders like autism, schizophrenia, and depression.
Researchers found that celecoxib, a widely prescribed pain and anti-inflammatory drug, slows the growth rate of neurofibromatosis type II (NF2) tumors in animal models. The study suggests that COX-2 inhibitors may have an impact on tumor formation and inflammatory responses.
Researchers at Scripps Research Institute develop a method to rapidly identify and optimize venoms for therapeutic use, finding potential treatments for multiple sclerosis and rheumatoid arthritis. They create a library of venom genes and use a cell-based selection system to find potent molecules that block key targets.
A team of scientists at TSRI has created a data-harvesting platform to automatically import and update genetic data from public databases. This allows researchers to focus on their own work instead of manually searching through large datasets.
Scientists at Scripps Research Institute designed a drug candidate that targets cancer-causing RNA, eliminating side effects and reducing tumor growth. The study demonstrates a clear breakthrough in precision medicine, using computational approaches to develop designer compounds.
Researchers at Scripps Research Institute discover how an immune system molecule affects the brain, leading to reduced appetite in cancer and other disease patients. The discovery points to potential targets for treating loss of appetite and supporting weight gain.
Scientists at Scripps Research Institute have received a grant to design precision drug candidates targeting disease-associated RNAs, aiming to develop patient-specific therapies for neurological diseases and cancer.
Researchers at Scripps Research Institute identify structural changes in estrogen receptor binding molecules linked to regulating cancer growth. The study reveals predictive features of ligand-specific signaling through the receptor, moving closer to developing more effective treatments for breast cancer.
A team of scientists from the Scripps Research Institute is studying the role of microRNAs in memory, sleep and synapse function. The five-year study will use Drosophila fruit flies to answer key questions about microRNA mechanisms in the brain.
Scientists at The Scripps Research Institute have solved the structure of a common virus's biological machinery, revealing important traits in Lassa virus. The research provides valuable insights into how to defend against its deadly cousin, Lassa fever, and may lead to the development of new treatments.
Scientists at Scripps Research Institute have devised a new molecule-building method that allows chemists to construct complex molecules starting from carboxylic acids. The method enables the easy synthesis of biologically active compounds, including drugs like Lipitor and Lyrica.
Scientists at Scripps Research Institute have developed a new electrochemistry-based method for allylic oxidation reactions, which are used in pharmaceuticals, flavor, and fragrance industries. The new method uses inexpensive, safe chemicals and is scalable, producing better yields and reducing toxic waste.
Researchers at TSRI have integrated biomedical data into Wikidata, enabling easy access and linking of genes, proteins, and more. The project aims to create a comprehensive, uniform database that can be searched and updated by anyone.
Scientists have identified a unique memory suppressor gene in Drosophila that could hold the key to developing new Alzheimer's treatments. The gene, known as DmSLC22A, is involved in filtering information and storing important parts when the brain prioritizes memories.
Researchers at TSRI have identified the first-ever immature HIV-neutralizing antibody, revealing a possible guide for developing an effective vaccine. The antibody, found in a Chinese patient, evolved rapidly and gained key traits within two years, contradicting previous theories.
Researchers at TSRI isolated a unique Treg cell from a mouse model of type 1 diabetes and discovered it originates in the thymus, giving rise to two functional states: an nTreg with active FoxP3 and a pre-nTreg without. This discovery opens new avenues for developing novel therapies to prevent autoimmune diseases.
A Scripps Research Institute team has received a $3.4 million grant to develop new therapeutics for addiction and mood disorders. The project focuses on the kappa opioid receptor, which helps regulate dopamine release, aiming to create potent new compounds with minimal side effects.
Scientists create a 'hollow' version of the plant virus cowpea mosaic virus (CPMV) which can be used as a carrier for drug molecules. This finding opens up new possibilities for cancer treatment and vaccine design.
Two unique enzymes, AIG1 and ADTRP, have been discovered that play a role in metabolism and inflammation, potentially targeting type 2 diabetes and inflammatory disorders. The enzymes are moderately inhibited by lipase inhibitors, suggesting they may be used to boost FAHFAs, which normalize glucose levels and reduce inflammation.
A research team has found that engineered HIV proteins can bind key immune cells present in most people, which could lead to the development of a broadly neutralizing antibody-inducing vaccine. The study's findings provide an encouraging foundation for an upcoming clinical trial.
Scientists at Scripps Research Institute (TSRI) have developed a 19-step process for synthesizing phorbol and its derivatives, providing access to powerful compounds for the development of new therapies. The method enables pharmaceutical researchers to make tiglianes in the laboratory, which are known for their biological activity and ...
Researchers at Scripps Florida aim to block breast cancer growth by targeting a specific microRNA that adapts cancer cells to low oxygen environments. Inhibiting this microRNA increases the sensitivity of cancer cells to death and makes them more vulnerable to chemotherapy.
Researchers found that acute and chronic kidney rejection are different parts of the same immune rejection process, making it a single entity at the molecular level. They identified interstitial fibrosis and tubular atrophy as an early warning sign of active but 'silent' rejection.
Researchers have identified a new molecular mechanism underlying neurodegeneration, which may lead to new diagnostics or therapeutic approaches for ALS. Cells construct protein clumps to protect against neurodegenerative diseases.
A new Scripps Research Institute study has identified specific genetic variations associated with increased susceptibility to bipolar disorder and other conditions. The research focuses on a gene called PDE10A, which produces proteins that regulate intracellular levels of cAMP, influencing biological processes like learning and memory.
Researchers will focus on brain-derived neurotrophic factor (BDNF) and its receptor TrkB to develop novel interventions for obesity. The study aims to understand the mechanisms governing energy balance in the body.
Scientists at Scripps Research Institute have identified a novel drug candidate that targets serine biosynthesis in cancer cells, inhibiting their growth. The new compound, CBR-5884, specifically targets the enzyme PHGDH, which is responsible for serine production, and shows promise in treating breast cancer, lung cancer, and melanoma.
Researchers at TSRI successfully sequenced individual neuron genomes and produced live mice carrying neuronal genomes in all of their cells. They found that each neuron contained an average of more than 100 mutations and accumulated more mutations in genes used frequently.
The study reveals the high-resolution structure of the HIV envelope protein, known as the Env trimer, in its natural form for the first time. The findings also include a detailed map of a vulnerable site at the base of this protein and the binding site of an antibody that can neutralize HIV.
Researchers solved the structure of a key coronavirus protein, revealing its conformation and potential vulnerabilities. This finding could guide future treatments for viruses like SARS and MERS.
Researchers at Scripps Florida Institute have developed a new method to predict the activity of stem cells in treating various diseases. The Clinical Indications Prediction scale uses TWIST1 levels to determine therapeutic potential, highlighting the importance of considering both angiogenesis and anti-inflammatory effects.
Researchers from Scripps Research Institute have identified microRNA miR-148a as a cause of autoimmune diseases like lupus. Elevated levels of this molecule allow self-reactive immune cells to escape and attack the body's own tissues.
A research team has identified a new group of powerful antibodies to fight Ebola virus, isolated from the blood of a survivor of the 2014 Ebola outbreak. The antibodies showed significant protection against the virus in mouse models and could guide the development of a vaccine or therapeutic.
Researchers assessed three methods of induced pluripotent stem cell production and found no significant risk of cancer-causing mutations. However, they warn that harmful mutations can accumulate later on as iPSCs multiply in lab cultures.
Researchers develop vaccine to prevent fentanyl overdose and addiction by targeting its molecular structure, which can be tailored to neutralize various variants of the drug. Successful preclinical tests show the vaccine protects against lethal doses of fentanyl, providing new hope in combating the opioid crisis.
Researchers at Scripps Research Institute are investigating mechanisms contributing to Huntington's disease, a fatal inherited disorder affecting movement and brain function. The study aims to clarify the Rhes signaling pathway's role in mitochondrial energy production and identify potential drug targets.
A new study led by TSRI scientists has found that oxygen sensing in the brain plays a role in metabolism and internal state sensing. The research discovered a connection between oxygen levels and fat reserves in animal models, suggesting a possible mechanism for regulating metabolism in humans.